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Abstract
Synucleinopathies, characterized by intracellular aggregation of a-synuclein protein, share a number of features in
pathology and disease progression. However, the vulnerable cell population differs significantly between the disorders,
despite being caused by the same protein. While the vulnerability of dopamine cells in the substantia nigra to a-synuclein
over-expression, and its link to Parkinson’s disease, is well studied, animal models recapitulating the cortical degeneration in
dementia with Lewy-bodies (DLB) are much less mature. The aim of this study was to develop a first rat model of
widespread progressive synucleinopathy throughout the forebrain using adeno-associated viral (AAV) vector mediated
gene delivery. Through bilateral injection of an AAV6 vector expressing human wild-type a-synuclein into the forebrain of
neonatal rats, we were able to achieve widespread, robust a-synuclein expression with preferential expression in the frontal
cortex. These animals displayed a progressive emergence of hyper-locomotion and dysregulated response to the
dopaminergic agonist apomorphine. The animals receiving the a-synuclein vector displayed significant a-synuclein
pathology including intra-cellular inclusion bodies, axonal pathology and elevated levels of phosphorylated a-synuclein,
accompanied by significant loss of cortical neurons and a progressive reduction in both cortical and striatal ChAT positive
interneurons. Furthermore, we found evidence of a-synuclein sequestered by IBA-1 positive microglia, which was coupled
with a distinct change in morphology. In areas of most prominent pathology, the total a-synuclein levels were increased to,
on average, two-fold, which is similar to the levels observed in patients with SNCA gene triplication, associated with cortical
Lewy body pathology. This study provides a novel rat model of progressive cortical synucleinopathy, showing for the first
time that cholinergic interneurons are vulnerable to a-synuclein over-expression. This animal model provides a powerful
new tool for studies of neuronal degeneration in conditions of widespread cortical a-synuclein pathology, such as DLB, as
well an attractive model for the exploration of novel biomarkers.
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Introduction
Synucleinopathies such as Parkinson’s disease (PD) and
dementia with Lewy bodies (DLB) are neurological disorders, that
while differing significantly in their symptomatic presentation, are
unified by a-synuclein aggregation and neuronal degeneration
[1,2]. Between these two distinct diagnoses lies also a spectrum of
disorders usually classified as PD with dementia (PDD) [3]. DLB is
one of the more common forms of dementia although the exact
proportion of all the dementia patients that is actually DLB (as
determined through neuropathological examination) is still not
settled. Studies indicate however, that DLB and vascular origins of
dementia are a close tie for the second most common source of
dementia after Alzheimer’s disease (AD) [4]. One of the striking
differentiators of DLB is thought to be caused by a-synuclein
toxicity localized to the cerebral cortices, leading to neurodegen-
eration and in particular, loss of cortical acetylcholine [5,6].
Together this causes frontal-subcortical and visio-spatial dysfunc-
tion, manifested by rapidly progressing dementia, apathy, depres-
sion and vivid visual hallucinations. Memory impairment may or
may not be part of the initial symptoms however. Through
insertion of the human a-synuclein gene in mice using transgenic
techniques, a number of useful animal models have been created
replicating a-synuclein pathology in PD [7–11]. Other useful
animal models have been created through targeted gene delivery
using viral vectors into the midbrain dopaminergic neurons of
mice, rats and non-human primates [12–16] or the combination of
both transgenics and viral vectors [17]. Transgenic animal models
have been important for understanding the neuronal pathology
and motor dysfunction seen in PD but lack the robust cortical
pathology, replicating the cognitive dysfunction seen in DLB.
Likewise, targeted gene delivery has been used mainly to over-
express a-synuclein in small, well defined brain regions like the
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substantia nigra pars compacta (SNpc), replicating primarily
motor symptoms of PD.
Targeting a large brain region, such as the cerebral cortices,
using recombinant viral vector mediated gene transfer has,
however, remained a challenge. To overcome the limitation in
viral vector diffusion in the adult brain parenchyma, a novel
strategy was proposed to inject the viral vector suspension into the
maturing brain during the first post-natal days [10,18,19]. This
mode of administration enables the vector diffusion and infection
to occur before maturation of axon myelination and gliogenesis,
the two processes that restrict free diffusion in the brain. Using this
methodology to deliver human a-synuclein in a recombinant
adeno-associated viral (AAV) serotype 6 vector (AAV6), we were
able to create a novel rat model exhibiting a-synuclein over-
expression mainly localized to the cerebral cortices, mimicking
primarily cerebral type of Lewy body disease [20]. These animals
displayed a progressive neurodegenerative phenotype with both
widespread degeneration of cholinergic interneurons and a
multitude of degenerative changes in the remaining cortical
neurons. This was associated with a changed behavioral pheno-




To evaluate the significance of a-synuclein over-expression
localized to the forebrain, neonatal Sprague Dawley rats received
under hypothermia a stereotactic, intra-parenchymal injection of
an AAV6 vector containing constructs expressing either a-
synuclein (n = 29) or GFP (n = 21). A third group, exposed only
to the hypothermic treatment, was kept as intact controls (n = 22).
All animals were evaluated for deficits in memory function in
Morris water maze; general anxiety; responsiveness of the
dopaminergic motor system and general motor function, with a
subgroup being tested at 8 weeks and the remainder tested at 6
months. Animals were sacrificed ten months post viral-injection
and evaluated for cortical neuronal degeneration using a modified
isotropic fractionation protocol [21]. In addition, further post
mortem analyses were performed using immunohistochemistry.
Animal Research
Six time-mated, pregnant female rats were purchased from
Charles River (Germany). After birth of the litter they were housed
one litter per cage with free access to food and water under a
12 hours light/12 hours dark cycle in a temperature-controlled
room. All experimental procedures performed in this study were
approved by the Ethical Committee for Use of Laboratory
Animals in the Lund-Malmö region.
Neonatal stereotaxic surgery
We used a neonatal model where pups were injected post-natal
day 2–4, in order to facilitate neuronal transduction throughout
the forebrain. Rat pups were anesthetized by hypothermia
through the following procedure; The pups were individually
sedated through rapid cooling in wet ice for 5 minutes where after
the animal was retained at <+4uC on a metal bed in the stereotax
throughout the surgery. A small hole was drilled through the skull
and the viral vector solution (viral titer: 3.5E12 gc/ml) was injected
bilaterally (1 ml/side) into the striatum at a flow rate of 0.2 ml/min
using a pulled glass capillary (60–80 mm I.D. and 120–160 mm
O.D.) attached to a 5 ml hamilton syringe. Target sites for the
injection were identified by using coordinates (relative to the
bregma): AP = +0.7; ML = +2.1; DV = 22.9 and the capillary was
left in position for one minute before retraction. Post-surgery, the
wound was closed using a surgical suture and the animal was
placed on a heating mat until awake.
Recombinant AAV vectors
AAV vector plasmids containing genes for either wild type
human a-synuclein or GFP, were expressed under the human
synapsin-1 promoter, ensuring neuron specific protein expression
[22]. The sequence was flanked 39 by the Woodchuck hepatitis
virus post-transcriptional regulatory element (WPRE) and termi-
nated with a SV40 derived poly-adenylation sequences to increase
mRNA cytosolic half-life. AAV vector constructs were produced
by dual-plasmid, calcium precipitation mediated transient trans-
fection of HEK-293 cells and purified by iodixanol gradient
centrifugation and anion exchange chromatography according to
[23]. Viral titers were determined by qPCR with primers
recognizing the WPRE sequence and diluted to match the
working titer of 3.5E12 GC/ml [24].
Evaluation of learning and memory impairments
Learning and memory deficits, due to a-synuclein over-
expression and toxicity, were evaluated in the Morris water maze
(MWM) task at six months post-injection. The MWM test was
performed as described in [25]. In brief, the rats learning and
global visio-spatial working memory abilities were assessed by
tracking the mean time for each animal to find a platform
submerged in a 2 m I.D. water filled tank, over a period of seven
days, 4 trials/day. Retention of the performance of the task was
assessed by additional trials in the MWM at one, three, seven and
21 days after the initial learning phase. Time spent searching for
the platform and total distance traveled was recorded using the
Ethovision 2.0 tracking software.
General motor and exploratory behavior
General motor function and exploratory behavior in animals
expressing a-synuclein was assessed by open field experiment at six
months post viral injection. Animals were placed in the open field
boxes (40640640 cm) and their, general mobility, rearing and
location was recorded over 1 hour by use of infrared sensors and
tracked by the San Diego Instruments tracking software. Activity
was recorded in a dark environment.
Assessment of dopaminergic pathways
Deficits in dopaminergic neurotransmission were evaluated in
the open field boxes following subcutaneous apomorphine
injection (1 mg/kg s.c.), at nine months post-injection. The
locomotor response to dopamine receptor activation by apomor-
phine was recorded over 1 hour, in the open field boxes, as above.
Tissue preparation
At 8 weeks post injection a subgroup of the animals were killed
(AAV6|a-Syn n = 4, AAV6|GFP, n = 6 Intact ctrl n = 8). At 10
months post AAV injection, all but seven of the remaining
(AAV6|a-Syn n = 22, AAV6|GFP n = 13 Intact ctrl n = 12) were
killed. The animals were deeply anesthetized by sodium pento-
barbital overdose (Apoteksbolaget, Sweden) and transcardially
perfused with 50 ml physiological saline solution followed by
250 ml of freshly prepared, ice-cold, 4% paraformaldehyde (PFA)
in 0.1 M phosphate buffer adjusted to pH = 7.4. The brains were
then removed and fixed further for 2 hours in cold PFA before
storing in 25% buffered sucrose for cryoprotection over at least
24 hours until further processing. The remaining seven animals
were killed by decapitation, where after the brain was removed
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and sliced in the coronal axis into two millimeter thick slices using
a brain mold. The striatal tissue, midbrain region, olfactory bulb
and two regions of the cerebral cortex (covering frontal or motor
cortex) were rapidly dissected and frozen individually on dry ice
and stored at 280uC until further analysis with western blot and
qPCR.
Neuronal quantification through isotropic fractionation
PFA-fixed complete cerebral cortex was dissected bilaterally
from AAV6|a-Syn (n = 6), AAV6|GFP (n = 5) and intact control
rats (n = 6), killed 10 months after viral injection. The protocol
used here is a modified version of that published by Herculano-
Houzel and collaborators [21]. The tissue was dissociated in 10 ml
of 0.5 M tri-sodium citrate buffer (pH 4.5) into homogenous nuclei
solutions using the GentleMacs dissociator (Miltenyi biotec).
Heating the sample between dissociation programs further
facilitated dissociation, allowing for a homogeneous nuclei
suspension. The nuclei solution was subjected to antigen retrieval
in 0.2 M boric acid (pH 9.0) at 70uC for one hour, followed by
blocking in 5% BSA for one hour. DAPI was added to stain all
nuclei, allowing for quantification of neuronal and non-neuronal
cells. In order to differentiate neuronal nuclei from non-neuronal
nuclei within the same sample, the nuclei were stained using a
neuronal specific monoclonal mouse anti-NeuN antibody (1:200;
MAB377 Millipore) in conjunction with a Dylight 550 goat, anti-
mouse secondary antibody (1:400; ab96880, Abcam). Samples
from the nuclei solution were then counted in a haemocytometer
using fluorescence-microscopy to calculate the concentration of
nuclei. In order to validate our modified protocol, the cerebellum
of the animals were also dissociated and quantified using the same
modified protocol.
Immunohistochemistry
The remaining PFA fixed brains were cut into 35 mm thick
coronal sections using a freezing microtome (Leica SM2000R) and
collected into 8 series and stored in anti-freeze solution (0.5M
sodium phosphate buffer, 30% glycerol and 30% ethylene glycol)
at 220uC until further processing.
Brain sections were evaluated for; human a-synuclein, rat a-
synuclein and GFP expression patterns, using the mouse 211 anti
a-synuclein antibody (1:2000; sc-12767, Santa Cruz), mouse anti
42/a-synuclein (1:1000; 610786, BD Biosciences) and chicken anti
GFP (1:20000; ab13970, Abcam) were used respectively. Presence
of phosphorylated a-synuclein using the Rabbit anti-Serine129-
phosphorylated a-synuclein (1:2000; ab59264, Abcam). In order
to evaluate the impact of a-synuclein over-expression on
cholinergic neurons, midbrain dopaminergic neurons, astrocytes
and microglia the goat anti-Choline acetyl transferase (1:500;
AB144P, Millipore), mouse anti-TH (1:10000; 22941, Immunos-
tar) Rabbit anti-GFAP (1:1000; ab7260, Abcam) and Rabbit anti-
IBA-1 (1:2000; 019-19741, Wako) were used respectively. In
addition, presence of phosphorylated Tau protein was assessed
using the rabbit anti-tau phospho S396 antibody (1:1000; ab32057
Abcam) Primary antibodies were visualized using biotinylated
secondary antibodies: horse anti mouse (1:250; BA2000, Vector
Laboratories), horse anti goat (1:250; BA9500, Vector laborato-
ries), goat anti rabbit (1:250; BA1000, Vector laboratories) and
goat anti chicken (1:250; BA9010, Vector laboratories). This was
followed by a 30 minute incubation with avidin-biotin peroxidase
solution (ABC Elite, Vector Laboratories) and developed by 3, 39-
diaminobenzidine (DAB) in 0.01% H2O2 color reaction. For
fluorescence microscopy analysis, secondary antibodies used
included: Dylight 550, goat anti mouse (1:250; ab96880, Abcam),
Dylight 488 goat anti mouse (1:250; ab96871) Alexa 488, goat anti
chicken (1:250; A11039, Life technologies), Alexa 488 goat anti
rabbit (1:250; A11008, Life technologies) and Alexa 546 donkey
anti goat (1:250; A11056 Life technologies). All secondary
antibodies were incubated for two hours in TBS-buffer.
Laser scanning confocal microscopy
Laser scanning confocal microscopy was conducted using either
a Leica SP2 or a Leica SP8 microscope. The confocal images were
captured using a HyD detector. All images were acquired with the
lasers activated in sequential mode, to avoid any bleed-through of
fluorescence. Solid state lasers at wavelengths 488 nm and 552 nm
were utilized to excite the respective fluorophores. The pinhole
was retained at Airy 1 for all acquisitions. For each acquisition at
the same magnification, identical settings were loaded for laser
power gain etc. Post acquisition, deconvolution was performed
using the ‘‘Deconvolution’’ plugin for ImageJ (developed by the
Biomedical Imaging Group [BIG] - EPFL – Switzerland http://
bigwww.epfl.ch/) utilizing the Richardson-Lucy algorithm and
applying point-spreads functions (PSFs) calculated for the specific
imaging equipment using the Gibson and Lanni model in the PSF
Generator (BIG, EPFL – Switzerland http://bigwww.epfl.ch/
algorithms/psfgenerator/). The same PFS models and deconvolu-
tion parameters were applied to all image stacks at the same
magnification. Orthogonal or maximum intensity projections were
generated using ImageJ64 (version 1.47).
Western blot analysis
In order to evaluate the expression levels of a-synuclein protein,
quantitative western blotting was used. Protein was extracted from
dissected olfactory bulb, frontal cortex, motor cortex and striatum
from AAV6|a-Syn (n = 3) AAV6|GFP (n = 2) and Intact ctrl
(n = 2) groups. The dissected tissue was homogenized in Trizol,
using the Fastprep-24 homogenizer (#116004500, MP Biomed-
icals) with lysing matrix D (#116913500, MP Biomedicals) Protein
was then extracted and purified, using the Invitrogen trizol protein
isolation protocol. Total extracted protein was quantified using the
Pierce BCA protein assay kit (#23227, Thermo scientific). For
total a-synuclein quantification, 20 mg of protein was loaded from
each sample into a 12 well mini-protean TGX gel (#456-1095; 4–
20%, 20 ml, BioRad) together with a standard of monomeric a-
synuclein (50, 100, 200 ng). The molecular weight of the protein
bands was determined using the Pageruler plus pre-stained protein
ladder 10–250 kDA (#26619, Thermo scientific) and run at 200
volts for 40 minutes. Proteins were transferred to a PVDF
membrane (0,2 mm) using the Transblot turbo transfer system
(BioRad). Following a washing step, the membrane was blocked
using 2% milk and incubated with the mouse anti 42/a-synuclein
(1:1000; 610786, BD Biosciences) over night in RT. Secondary
HRP-conjugated goat anti mouse (1:10000; 115-035-174, Jackson
ImmunoResearch) were used and incubated in 2% milk for
2 hours. The membrane was then visualized using the Immun-
Star HRP Chemiluminescent Substrate Kit (#170-5040, BioRad)
with fluorescence detected using the Chemidoc MP imaging
system (BioRad). Total a-synuclein was then quantified relative to
the human a-synuclein monomeric standards.
Quantitative PCR
Brain areas were carefully dissected and swiftly flash frozen
using dry ice. mRNA was then extracted using Trizol (Invitrogen)
followed by Aurum Total RNA Mini Kit (BioRad). 500 ng total
mRNA was used in a cDNA synthesis using iScript cDNA
Synthesis Kit (BioRad) with the following program; 25uC for
5 minutes, 42uC for 30 minutes and finally 85uC for 5 minutes.
Novel AAV-Based Rat Model of Cortical Synucleinopathy
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e100869
Specific primer pairs for rat a-synuclein (fwd 59-GCTGGGAA-
CATTGCTGCT-39, rev 59-TGGGTACCCTTCTTCACCC-39)
and human a-synuclein (fwd 59- CAGGGAGCATTGCAGCA39,
rev 59-GTGGGGCTCCTTCTTCATTC-39) were designed and
validated on plasmid cDNA containing either rat or human a-
synuclein. Both primer pairs were used on both cDNA and a fold
change of 47000 was observed when using rat specific primers on
human cDNA and 112500 fold change when using human specific
primers on rat cDNA. Hence the primers were considered to be
species specific. Prior to qPCR, primer efficiency was determined
by qPCR on a 5 step dilution series of template, primer efficiencies
were calculated and values were used in normalization.
All qPCR results were normalized to three reference genes,
ActB (fwd 59- AAGTCCCTCACCCTCCCAAAAG-39, rev 59-
AAGCAATGCTGTCACCTTCCC-39) GAPDH (fwd 59-
CAACTCCCTCAAGATTGTCAGCAA-39, rev 59-GGCATG-
GACTGTGGTCATGA-39) and TBP (fwd 59-TGGGATTG-
TACCACAGCTCCA-39, rev 59-CTCATGATGACTGCAG-
CAAACC-39). All plates were run with inter-run calibrators and
–RT controls.
Each reaction contained 10 ml SSoAdvanced SYBR Green
Supermix (BioRad), 0.5 mM of each primer, 1 ml cDNA and 8 ml
H20. All samples were run in triplicates with the following
program; 95uC for 30 sec, 95u for 5 sec and 60uC for 20 sec (39
cycles), followed by a melt curve ranging from 65uC to 95uC with
0.5uC increments every fifth second.
Transmission electron microscopy
Tissue for TEM analysis was fixed using 1.5% paraformalde-
hyde with 1.5% glutaraldehyde in 0.1 M Sorensen’s buffer for
osmium tetroxide staining. The tissue was then fixed in 1%
osmium tetroxide in 0.1 M Sorensen’s buffer and progressively
dehydrated in acetone, starting at 30% up to 100% acetone. The
tissue was then embedded using 1:1 acetone and epoxy and
counterstained using 4% uranyl acetate and 1% lead citrate.
Tissue used for immunogold staining was fixed using 1.5%
paraformaldehyde with 0.5% glutaraldehyde and progressively
dehydrated in ethanol, using the Leica AFS protocol and then
embedded in Lowicryl HM20. The tissue was sectioned using the
Leica UC7 ultramicrotome and sectioned into 50–60 nm slices.
For immunostaining, gold conjugated syn 211 antibodies (santa-
cruz 1:200) were used and counterstained using 4% uranyl
actetate. All tissue sections were analyzed using the Tecnai biotwin
120 KV microscope.
Statistical analyses
Statistical analysis was performed using the SPSS 21 software.
Datasets from the open field task, total neuronal quantification
and quantification of ChAT positive neurons were tested for
statistical significance using one-way ANOVA with Newman-
Keuls post hoc test for multiple comparisons. Datasets for total
human a-synuclein mRNA expression and total protein levels
were tested for statistical significance using the Mann-Whitney
rank order test.
Results
In preparation for the described study, we compared AAV
serotypes 5 and 6 in the neonatal rat transduction model. We
found that the use of the AAV6 serotype ensured a broad spread of
expression, mainly localized to the cerebral cortices while the
AAV5 serotype, while displaying a broad spread, did not show a
great affinity to the cerebral cortices. Stereotactic surgery on
neonatal animals has in the past presented with its own challenges.
However, survival rate of over 80% was achieved in our study by
inducing anesthesia through hypothermia on neonatal (post-natal
day 2–4) animals. In total, this resulted in 29 animals with a broad
a-synuclein over-expression, localized to the cerebral cortices. To
characterize disease progression, neuronal degeneration and
pathology, the animals were exposed to a battery of behavior
tests, assessing both motor and cognitive function, at either 8
weeks or 26 weeks post viral injections.
AAV6|a-Syn animals display increased exploratory motor
behavior and dysregulated response to dopamine
agonist, but no memory impairment
AAV6|a-Syn animals displayed no significant difference in
exploratory behavior in the open field task, relative to control
groups at 8 weeks post viral injection (Fig. 1A). However, at six
months post viral injection, AAV6|a-Syn animals showed
significantly increased naive exploratory behavior relative to both
the AAV6|GFP (p = 0.01) and the intact Ctrl (p = 0.02) groups,
indicating abnormal locomotor behavior (Fig. 1B). AAV6|GFP
animals on the other hand, exhibited decreased ambulatory
locomotion relative to both AAV6|a-Syn and intact Ctrl animals,
indicating reduced exploratory behavior (Fig. 1B).
To investigate forebrain dopaminergic neurotransmission,
animals were injected with the dopaminergic agonist apomorphine
(1 mg/kg s.c.) and re-evaluated in the open field task. AAV6|a-
Syn animals displayed a significantly lower locomotor activity
relative to AAV6|GFP (p,0.05) with a strong trend relative to
intact Ctrls, indicating a desensitization of dopaminergic striatal
receptors or loss of postsynaptic neuronal targets at 6 months with
indications of dysregulation already at 8 weeks (Fig. 1 A–B).
The cerebral cortices are important for many broad cognitive
functions such as memory consolidation and retrieval and
degeneration of cortical neurons in combination with the loss of
cholinergic pathways is thought to contribute to dementia in DLB
patients. To assess the role of a-synuclein over-expression on
learning and memory formation rats were evaluated in Morris
Water maze (MWM) task. Rats over-expressing a-synuclein
displayed no learning deficits in the MWM task (Fig. 1C) and
no significant difference between AAV6|a-Syn animals and
control groups was observed in consecutive trials during the same
trial day, indicating that the hippocampal dependent spatial
working memory remained intact. We also evaluated the average
swim speed of the animals to evaluate if the motor dysfunction
observed in tests above could have been a confounding factor in
this test. No differences were observed in the swim speed between
the groups.
Neonatal AAV6 injection induces widespread a-synuclein
expression throughout the forebrain
The novel paradigm of neonatal viral delivery, using the AAV6
serotype, induced substantial expression of human a-synuclein
throughout the forebrain, mainly localized to the cerebral cortices
and striatum, visualized using the Syn211 antibody, previously
shown to be selective towards human a-synuclein [26] (Fig. 2A).
GFP expression from the control vector closely matched that of
human a-synuclein (Fig. 2B), suggesting similar distribution and
spread. Neurons positive for human a-synuclein were found to be
widely dispersed throughout all cortical layers and in both
projection and interneurons. Topographically, the main expres-
sion of human a-synuclein reached the highest levels in the M1/
M2 motor cortices, with lower expression apparent in the pre- and
infra-limbic frontal cortical areas. In addition, immunostaining
revealed major anterograde transport of human a-synuclein,
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through the cortico-thalamic and cortico-spinal tracts, continuing
through the pyramids of the medulla oblongata and persisting
through the cortico-spinal tract along the ventro-medial spinal
cord (Fig. 2A). Staining for human a-synuclein was also observed
to extend along the striato-nigral pathway to the globus pallidus
and the substantia nigra pars reticulata (SNpr), indicating
substantial anterograde transport. Retrograde transport of human
a-synuclein to the dopamine neurons in the SNpc was, however,
not readily apparent. Large numbers of a-synuclein positive
interneurons were also apparent within the olfactory bulb,
suggesting efficient transduction of neuronal progenitor cells
within the rostral migratory stream (RMS).
Human a-synuclein gene expression and protein levels
are increased throughout the forebrain
To evaluate the gene and protein levels of human a-synuclein,
several regions of the forebrain and midbrain were dissected at 40
weeks post-injection and evaluated by qPCR and Western
blotting. To allow for quantification of human a-synuclein and
rat a-synuclein mRNAs independently, primers specific for human
a-synuclein were developed and validated. Using these primers on
both human and rat a-synuclein cDNA, we found a SNR between
47000:1 and 112500:1, i.e., showing sufficient specificity. qPCR
analysis revealed significant amounts of human a-synuclein
mRNA levels in the striatum (p = 0.034), frontal (p = 0.034) and
motor cortices (p = 0.034). Interestingly, significant levels of
human a-synuclein were also detected in the olfactory bulb
(p = 0.034) and ventral midbrain (most likely in axon terminals
from medium spiny neurons projecting to the SNpr) (p = 0.034),
although to a much lesser degree (Fig. 3A). To investigate if
expression of human a-synuclein promotes any regulatory effect
on mRNA levels of endogenous rat a-synuclein, primers specific
for rat a-synuclein were used. qPCR analysis revealed no
significant differences in rat a-synuclein between the treatment
groups in any of the brain regions investigated, suggesting that
over-expression of human a-synuclein does not regulate expression
of endogenous rat a-synuclein (Fig. 3B).
Total rat and human a-synuclein protein expression was
evaluated using Western blotting with monomeric a-synuclein
protein as a standard detected with an antibody previously shown
to display comparable affinity to rat and human a-synuclein [27]
(Fig. 3C). AAV6|a-Syn animals showed a significant, 2–3 fold
increase of total a-synuclein levels within the olfactory bulb
(p = 0.034), striatum (p = 0.034) and the cerebral motor cortices
(p = 0.034) were the expression levels of a-synuclein were found to
be the highest (Fig. 3D). Interestingly, dimeric a-synuclein was
present in all AAV6|a-Syn animals, even though proteins were
extracted using SDS and run on a non-native gel, suggesting that
some insoluble a-synuclein aggregates may have formed in the
AAV6|a-Syn animals (Fig. 3C).
a-Synuclein induces broad pathologies and increased
phosphorylation throughout the forebrain
IHC staining revealed large numbers of neurons within the
cerebral cortices and striatum expressing human a-synuclein.
Neuronal cells displayed diffuse human a-synuclein staining
Figure 1. Behavioral assessment of motor and memory
functions. At 8 weeks post viral injection, animals in the group
receiving the AAV-6 a-synuclein vector (AAV6|a-Syn) displayed no
significant difference in either naı̈ve locomotion, or after subcutaneous
apomorphine injection (1 mg/kg) relative to control groups (Intact Ctrl)
or animals receiving the control vector (AAV6|GFP), in the open field
task (A). However, at 26 wks post viral injection, the AAV6|a-Syn animals
displayed a significant increase in naı̈ve locomotion relative to control
groups. In addition, the AAV6|a-Syn animals displayed significantly
decreased response to apomorphine (1 mg/kg) relative to AAV6|GFP
animals, suggesting dysregulation of the dopamine system (B). AAV6|a-
Syn animals, trained in the Morris water maze (MWM) for seven
consecutive days, exhibited no significant deficits in visio-spatial
memory and learning (C9) and were also able to retain the learned
task up to 21 days after the initial training period (C0). (* = p,0.05, one-
way ANOVA with Newman-Keuls post hoc test). Data is expressed as
mean 6 SEM.
doi:10.1371/journal.pone.0100869.g001
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throughout the soma accompanied by aggregate pathologies
ranging from small a-synuclein positive puncta to larger inclusions
(Fig. 4B), as well as large a-synuclein positive axonal swellings that
were widespread throughout the cerebral cortices and the striatum
(Fig. 4 A–H). Alpha-synuclein staining within the thalamic nuclei
and SNpr revealed abundant a-synuclein positive projections but
no transduced cell bodies (Fig. 4 I–P). Large pathologies with
intense a-synuclein staining in both the thalamic nuclei and the
SNpr were thought to be exceptionally large axonal swellings,
created as a result of blocked anterograde transport and a-
synuclein accumulation (see EM data below).
Phosphorylation of a-synuclein, at serine 129, (pSer-129) is
thought to be a post-transcriptional modification associated with
a-synuclein aggregation and pathology. Staining for pSer-129 a-
synuclein revealed a significant increase of phosphorylation
throughout the cerebral cortical layers and striatum. Phosphory-
lation of a-synuclein was mainly found within the neuronal cell
soma and, to a lesser extent, in cortical and striatal projections
(Fig. 4 C and K). Moderately increased phosphorylation was
apparent in thalamic nuclei and the SNpr, although to a much
lesser extent than within the cerebral cortices and the striatum and
was notably different to the Syn211 human a-synuclein staining
pattern. These findings suggest that phosphorylation takes place
mainly in the cell soma and may be less prone to anterograde
transport, relative to non-phosphorylated a-synuclein in vivo.
Phosphorylated a-synuclein appeared to co-express with human
a-synuclein in the neuronal cell soma (Fig. 5 A–B), mainly as
intracellular puncta and within larger inclusion bodies (Fig. 5 C–
F), suggesting that phosphorylated a-synuclein may be more prone
to aggregation in vivo. Hyper-phosphorylation of AD associated
Tau protein, may be present simultaneously in patients with DLB
and AD was also evaluated by immunohistochemistry. However,
no Tau protein hyper-phosphorylated at the pSer396 residue
could be identified in any of the brain regions affected by a-
synuclein over-expression (data not shown).
Human a-synuclein localizes to cell soma, cell nuclei,
axonal swellings and synapses, and is correlated with
neuronal pathology
Electron microscopy on Osmium tetroxide (OsO4) treated
brain sections revealed a large number of cells with apoptotic
morphology, characterized by fragmentation of the nuclear
membrane, distended rough endoplasmic reticulum and swollen
mitochondria (Fig. 6). Apoptotic cell morphology ranged from
early apoptotic features to small, condensed cell fragments. In
some cases, autophagosomes derived from the Golgi were also
identified within highly apoptotic cells (Fig. 7 A–B). Using
immunogold staining against human a-synuclein (Syn211), apo-
ptotic cells presented with large amounts of nuclear associated a-
synuclein. The a-synuclein found in the nuclei appeared mainly
associated with areas of chromatin (Fig. 6 B), supporting previous
findings that a-synuclein may associate with DNA-histone
complexes and promote neurotoxicity. Diffuse staining of human
a-synuclein was observed in numerous cells, however, a-synuclein
was also present as larger inclusion bodies and fibrillar structures
(Fig. 7 C–D), some within vesicle structures that may be part of the
lysosomal system (Fig. 7 E–F). Cells with degenerative morphology
were often found to contain large numbers of large, swollen
mitochondria (Fig. 6 I–J). Human a-synuclein was found to be
associated with such pathological mitochondria (Fig. 6 I–J), as well
as to mitochondria without any clear pathological morphology.
Axonal swellings were also a relatively common finding in animals
expressing human a-synuclein. These swellings appeared as large,
empty structures, devoid of characteristic microtubules (Fig. 6 E).
Figure 2. Histological overview of transduced brain regions. At
40 weeks post AAV injection, the long-term group was sacrificed and
coronal brain sections stained with antibodies recognizing the
respective transgene, syn211 against human a-Synuclein and a chicken
polyclonal antibody against GFP. Intact control animals (Intact ctrl) were
stained with both antibodies to confirm specificity (only syn211 shown).
Transduction pattern was very similar in both the AAV6|a-Syn and the
AAV6|GFP group with a very intense immunoreactivity in the cerebral
cortex (A,B). Very low staining was observed in the Intact ctrl animals
with the syn211 antibody (C), confirming the specificity of this antibody
towards human a-synuclein. The expression pattern of human a-Syn (A)
differed substantially from the expression pattern of endogenous rat a-
synuclein as observer through staining with another antibody
recognizing also the rat a-synuclein (BD Biosciences 610786) (D). For
clarity, sections from the spinal cord are not to scale with the brain
sections and have been enlarged to 200%.
doi:10.1371/journal.pone.0100869.g002
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Figure 3. Molecular and biochemical quantification of a-synuclein expression. At 40 weeks post AAV injection, a separate group of animals
was sacrificed for molecular and biochemical assessments. Fresh brain tissue was rapidly dissected into five regions where a-synuclein expression had
been observed in the histological observations (Figure 1); striatum, motor cortex, frontal cortex, olfactory bulb and substantia nigra. Using trizol,
mRNA and protein were extracted from each region and assessed using quantitative RT-PCR (A–B) and western blot respectively (C–D). For qPCR, two
new primer pairs were designed, one specific for human a-synuclein (A) and one pair for rat a-synuclein (B). Both displayed very high specificity
without cross-amplification .47000:1). Human a-synuclein mRNA was robustly expressed in all regions tested in the AAV6|a-Syn animals without any
detection in the control groups. Interestingly a-synuclein mRNA was also detected in the olfactory bulb, further confirming the observation that
neuroblasts in the RMS were transduced in the neonatal brain. No changes were observed in the mRNA expression of endogenous a-synuclein (B). All
data in A and B are normalized to three housekeeping genes (Gap-DH, TBP and b-actin). Total a-synuclein protein levels were quantified using
quantitative western blot (C–D). The known amounts of human monomeric a-synuclein was loaded on each blot to create a standard curve (C9) and
total a-synuclein was detected using an antibody previously shown to have comparable affinity to rodent and human a-synuclein in WB. Final
expression levels were finally normalized to b-actin. Blot in (C) shows a representative blot of tissue from the motor cortex. Interestingly, despite
samples boiled in SDS and run on SDS containing gels, samples from the AAV6|a-Syn animals displayed a immunoreactive band at exactly double the
size of monomeric a-synuclein (arrow in C), an observation seen in all regions. This correlated with intensity of monomeric expression and was never
found in any of the control animals. Total a-synuclein levels were increased up to four-fold in regions of the cortex near the injection site (D) with
lower, although still significant, increase in the frontal cortex. (* = significant increase over control groups p,0.05 in Mann–Whitney U test). Data is
expressed as mean 6 SEM.
doi:10.1371/journal.pone.0100869.g003
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Figure 4. High-power histological analysis of a-synuclein expression. Histological analysis of the cerebral cortices revealed high expression
of human a-synuclein (syn211) within the soma and axonal projections of the cortical neurons. These neurons displayed a high incidence of a-
synuclein punctates within their soma (arrows), while phosphorylated a-synuclein (P-ser129) was highly increased within the neuronal soma, and to a
lesser extent within the axonal projections (A–D). Striatal analysis revealed high incidence of neurons with prominent expression of human a-
synuclein, with Lewy neurite’s being a common find (arrow). Phosphorylation of a-synuclein within the striatal neurons was also upregulated (E–H)
Projections within the thalamic nuclei were found to contain high levels of human a-synuclein with large a-synuclein positive structures, believed to
be large axonal swellings, were present throughout the thalamus (arrows) (I–L). Large axonal swellings were also present to a large extent in the SNpR
(arrows) while phosphorylation of a-synuclein appeared as only moderately increased (M–P). The neonatal injection of the AAV6 serotype displays an
interesting ability to also infect neuronal progenitors within the rostral migratory stream (RMS) or the sub-ventricular zone. This is seen as mature
neurons within the olfactory bulb expressing high levels of human a-synuclein (R–S). These neurons appear with healthy morphology with a-
synuclein distributed throw-out the neuropil (S). Dotted lines within the cerebral cortex denote the position of the tissue punch taken for TEM
analysis.
doi:10.1371/journal.pone.0100869.g004
Novel AAV-Based Rat Model of Cortical Synucleinopathy
PLOS ONE | www.plosone.org 8 July 2014 | Volume 9 | Issue 7 | e100869
In sections stained for human a-synuclein, these large axonal
swellings were found to be full of human a-synuclein, suggesting a-
synuclein driven pathology (Fig. 6 F). Finally, large amounts of
human a-synuclein was also found within synapses, although no
morphological pathologies were apparent (Fig. 6 M–N).
AAV-mediated a-synuclein over-expression causes
cortical neurodegeneration
Quantification of forebrain neurons is essential to evaluate a-
synuclein induced toxicity that may lead to neuronal degeneration.
Thus, a modified isotropic fractionation protocol for neuronal and
non-neuronal quantification was developed. Assessing such a large
and heterogeneous brain region is difficult and time consuming
using established stereological methods, which require frequent
sampling of homogeneous regions to be accurate. Isotropic
fractionation, on the other hand, allows cell quantification and
accurate comparison between samples, regardless of differences in
volume [21,28]. Therefore, we used a modified protocol based on
the isotropic fractionation method to obtain quick and accurate
quantification of neurons throughout the forebrain (Fig. 8 A–B).
Intact control animals displayed a mean total of around 43000
NeuN positive cells/mg tissue. AAV6|a-Syn animals, killed 40
weeks after vector injection, differed significantly (p = 0.02), with
an average of 34000 NeuN positive cells/mg tissue, from that seen
in intact control and GFP expressing animals (Fig. 8 C). Control
animals had a mean total value of around 67000 DAPI positive
cells/mg tissue, while total cells in animals expressing human a-
synuclein displayed a non-significant reduction in mean total cells
of around 63000 DAPI positive cells/mg tissue (Fig. 8 D). Our
novel isotropic fractionation protocol was evaluated and validated
by quantifying total cell and total neuronal populations in the
cerebellum in all groups, as the cerebellum, a structure located
outside the vector-transduced parts of the brain. No significant
difference in the number of total DAPI positive and NeuN positive
cells was found between the animals expressing human a-synuclein
and the two control groups.
a-Synuclein over-expression induces progressive
neuronal degeneration and loss of cholinergic cortical
and striatal interneurons
Reduction in cortical acetylcholine levels has been reported to
play a major role in the cognitive deficits observed in DLB
patients. To evaluate the loss of cholinergic neurons in the cortex
due to a-synuclein over-expression, stereological analysis of ChAT
positive neurons in the dorso-medial cerebral cortices was
performed on animals 10 months post-injection. The stereological
analysis revealed a significant neuronal loss (p,0.05) of ChAT
positive cholinergic neurons within the cerebral cortices, relative to
GFP and intact controls, suggesting a-synuclein specific toxicity
(Fig. 9 H, J). In order to assess if the observed neuronal
degeneration was progressive or was a result of an earlier, acute
degeneration in response to a-synuclein over-expression, animals
expressing human a-synuclein were evaluated 8 weeks post-
injection. At this time-point, no neuronal degeneration in cortical
neuronal ChAT+ cells could be observed, suggesting a progressive
neuronal loss (Fig. 9 B,D). As a-synuclein over-expression is also
present in the striatum and the cholinergic interneurons there may
be part of the dysregulatory response to apomorphine in the open
field task, stereological analysis of the striatal cholinergic
interneurons was also performed. Animals expressing human a-
synuclein displayed a significant neuronal loss of cholinergic
interneurons at 10 months post viral injection (Fig. 9 G,I), while
Figure 5. Analysis of cortical pathologies in AAV6|a-Syn
animals using double fluorescence confocal microscopy.
Human a-synuclein was found to be localized both in the nucleus
and the cytosol of transduced neurons (A–B0). In cells with lower
expression level, expression was mostly confined to the cytosol (A9),
while with increase of the expression, nuclear localization increased
substantially (B9). Interestingly, a-synuclein localized to the nucleus
appeared to be relatively more phosphorylated than cytosolic a-
synuclein (inset in A, A0 and B0). Phosphorylated human a-synuclein also
appeared in larger inclusion bodies outside the nucleus. These
appeared both as large hollow spheres (C–D0), assemblies of fibril-
shaped protein (E–E0) and flat sheets (F–F0). In all these cases, the
majority of the aggregated protein appeared to be phosphorylated at
serine 129 (C0, D0, D0 and F0). If these inclusion bodies are localized
inside or outside the cell membrane cannot be conclusively determined
at this point. Images in panels A, C and E are displayed as maximum
intensity projections and B, D and F as orthogonal projections. All
captured using sequential laser scanning at Airy 1 pinhole.
doi:10.1371/journal.pone.0100869.g005
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this was not observed in animals at 8 weeks post viral injection
(Fig. 9 A,C), again, suggesting a progressive neuronal loss.
a-Synuclein over-expression, induces activation and
promotes pathological morphology in resident microglia
Microglial activation and reactivity has been found to be
increased in the brain of DLB patients [29] and may contribute to
disease progression. In our animal model, over-expression of
human a-synuclein was restricted to neurons through the
utilization of the neuron-specific human Synapsin-1 promoter
[22]. Nevertheless, a-synuclein over-expression caused distinct
phenotypic changes in microglial morphology. First, a large
fraction of microglial cells were found with highly condensed
cytoplasm and nuclei, with a loss of extending processes (Fig. 10
A), indicating increased activity and reactivity in response to a-
synuclein over-expression. The second change was observed as a
general elongation of the microglial cytoplasm coupled with loss of
extending processes, indicating increased activity and migration
Figure 6. Transmission electron microscopy assessing a-synuclein localization and associated pathologies. Analysis of the cerebral
cortices through electron microscopy revealed a large number of apoptotic neurons. These neurons were identified by morphological features, such
as large, swollen mitochondria, vacuole formation and disruption of the nuclear envelope (e.g., * in A). Immunogold staining for human a-synuclein
(Syn211) revealed a high presence of nuclear associated a-synculein in apoptotic neurons (black 10 nm dots marked by arrows in B) in addition to
that of the soma (A–D). Large axonal swellings were also a common pathological finding throughout the cerebral cortices (* in C). These were found
to have large accumulations of human a-synuclein (arrows in F) and also appeared to associate with the cellular membrane (E–H). Large and swollen
mitochondria present in neuronal cells, as well as within the axons (* in I) appeared associated with large amounts of human a-synuclein (I–L). Human
a-synuclein was also found to be present to a large extent in synapses of the cerebral cortices (M–P), However, these synapses appeared largely of
normal morphology. The antibody staining in B–C, F–G, J–K and N–O is visualized using immunogold particles of 10 nm in diameter.
doi:10.1371/journal.pone.0100869.g006
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(Fig. 10 C). These morphological changes were readily identified
within the main transduction area of the cerebral cortices but not
in proximity to a-synuclein positive projections in other brain
regions. The morphological changes were also not observed in
AAV6|GFP or intact control animals (Fig. 10 B, D). To investigate
if the morphological changes in the microglial cells could be a
result of direct uptake of human a-synuclein, tissue sections were
examined using confocal microscopy (Fig. 10 E–F). Human a-
synuclein was found within microglial cells from AAV6|a-Syn
animals and was present mainly as intracellular inclusion bodies
and within IBA-1 positive projections throughout the cerebral
cortices (Fig. 10 E). These cells were mostly found in close
proximity to human a-synuclein positive neurons displaying
degenerative morphology. In addition, some microglia were
observed to contain large vesicular structures loaded with a-
synuclein (Fig. 10 E), indicative of an active clearance mechanism.
Figure 7. Immunogold and osmium developed TEM reveals a-
synuclein associated, intracellular fibrillar structures and
increase of autophagosomes. Additional electron microscopy
revealed a number of pathological features, including apoptotic body
cell remnants, present throughout the cerebral cortices (A). Autopha-
gosomes forming from the Golgi (arrow) was a feature also present in
cells with a high degree of apoptotic morphology (B). Human a-
synuclein immunogold (syn211) staining revealed fibrillar-like structures
(arrow in C) as well as larger inclusion bodies (D) present within the
soma and axons (C–D). Subjectively, granular aggregates of lipofucins
appeared to be a more common feature in a-synuclein expressing
animals, suggesting lysosomal/proteosomal pathology. However, no
absolute quantification was possible. (E–F).
doi:10.1371/journal.pone.0100869.g007
Figure 8. Modified isotropic fractionation for neuronal quan-
tification reveals broad-spread cortical degeneration. Principals
of modified isotropic fractionation for neuronal quantification (A). PFA
fixed cerebral cortices were dissected and dissociated using the
GentleMacs tissue dissociator. Following centrifugation and washing
only a nuclear fraction remained. The nuclear fraction was stained for
DAPI and the NeuN neuronal marker and counted in a haemocytom-
eter, using florescence microscopy (B). Quantification revealed a
significant neuronal degeneration within the cerebral cortices of
animals expressing a-synuclein, relative to controls (C). There was
however, no significant neuronal loss in the cerebellum, a region
not expressing human a-synuclein, using our modified isotropic
fractionation protocol (AAV6|a-Syn 463.1624.96103, AAV6|GFP
475.1615.16103, Intact ctrl 506.7612.16103. (* = p,0.05, one-way
ANOVA with Newman-Keuls post hoc test). Data is expressed as mean
6 SEM.
doi:10.1371/journal.pone.0100869.g008
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Figure 9. Quantification of cholinergic neurons regions with high expression of human a-synuclein. Immunohistochemical staining of
ChAT positive Cholinergic interneurons using DAB precipitation coloring of the striatum and cerebral cortex revealed a significant, progressive loss in
both the striatum and the medial lateral Cerebral cortices starting later than 8 wks post viral injection. At the earliest time point (8 wks) no loss of
cholinergic neurons was apparent in either the striatum (A) or the cerebral cortices (B). However, ChAT + interneurons were qualitatively lighter
stained with fewer processes clearly visible (C–D) relative to GFP injected animals (E–F). At 10 months post viral injection, however, there was a
significant reduction on Cholinergic interneurons in both Striatum (G) and Cortex (H) of AAV6|a-Syn animals compared to both AAV6|GFP and Intact
ctrl animals. At this time point, ChAT staining revealed a high degree of clearance of cholinergic neurons within the striatum (I) and medial lateral
cerebral cortices (J), relative to GFP injected animals (K–L). (* = p,0.05, one-way ANOVA with Newman-Keuls post hoc test). Data is expressed as
mean 6 SEM.
doi:10.1371/journal.pone.0100869.g009
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Taken together, these data suggest that microglial uptake of
human a-synuclein participates in the ongoing pathology in this
animal model.
Discussion
In this study we set out to develop a novel rat model of
widespread progressive forebrain synucleinopathy. The goal was
to achieve pathology restricted to this region without affecting
other parts of the brain, such as hippocampus and the substantia
nigra. Rodent models of diverse forms of synucleinopathy, such as
PD, and DLB, have been valuable in determining both
vulnerability factors and the specific contribution of a-synuclein-
induced pathology to the phenotype [30–34]. In a-synuclein
overexpressing transgenic mice, however, the specific contribution
of pathology induced in different parts of the brain has been
difficult to achieve, since most of these transgenic mouse strains
express the protein in many parts of the brain [11,35,36].
Through the neonatal AAV6-mediated gene delivery paradigm
together with the injection coordinates utilized in this experiment,
a-synuclein expression was mainly expressed within neurons in the
M1–M2 regions and to a lesser extent also in the pre- and infra-
limbic prefrontal cortex and the striatum. The mechanism behind
the prominent cortical transduction following AAV injection into
the striatum of neonatal rats is currently unknown. It is clear that
AAV particles diffuse much more efficiently in the neonatal brain,
compared that that in adults [18,19]. This is not only due to the
smaller size of the brain in neonates but most probably also to the
absence of myelinated structures that are known to restrict the
diffusion of the viral particles from the injection site. In
preparation for this experiment we compared the usefulness of
two different AAV serotypes, AAV5, which has been used in
previous studies [18,19], and AAV6, which is our preferred
serotype. We found that AAV5 induced broad expression of
human a-synuclein throughout the forebrain but did not display
the same high affinity for neurons in the neocortex as the AAV6
vector. Thus, the properties of the AAV6 capsid are particularly
favorable for targeting neurons in the neocortex. The broad
transduction pattern is not believed to be caused by a leakage of
the vector into the CSF, as neurons in the hippocampus and other
structures surrounding the caudal parts of the ventricles are not
transduced. We have also conducted pilot studies injecting the
AAV6 vector directly into the ventricles and the resulting
transduction pattern is then restricted mainly to the ependymal
cells with very little parenchymal penetration. The pattern of a-
synuclein expression in the olfactory bulb, confined to a subset of
interneurons, suggest that the AAV6 vector is efficient in
transducing the neural progenitors in the subventricular zone
and/or the RMS. This labeling, which was not observed with the
AAV5 vector, further supports the beneficial permissiveness of
AAV6 to immature and still dividing neural progenitors. Postnatal
cell division in the cerebral cortex [28] may therefore also
contribute to the efficient cortical transduction obtained with the
AAV6 vector. a-Synuclein expression did not extend into the
Figure 10. Morphological changes and evidence of a-synuclein
uptake in IBA-1 positive microglia. Immunohistochemical staining
of IBA-1 using DAB precipitation coloring in the cerebral cortex revealed
a substantial change in the microglial morphology in the cortex of
AAV6|a-Syn animals compared to AAV6|GFP and Intact ctrl animals at 10
months post AAV injection (A–D). In the regions overlapping with the
most intense human a-synuclein over-expression, most microglial cells
appeared with very few visible processes and majority of the IBA-1
positive staining localized to the nucleus (A), this stood in stark contrast
to the normal IBA-1 staining of microglia in the corresponding cortical
regions of AAV6|GFP animals (B). In surrounding cortical regions, the
microglial morphology in AAV6|a-Syn animals showed a second distinct
morphology, with elongated cell body and fewer processer, suggesting
a migratory profile (C). Using double-labeled, fluorescence with IBA-1
and human a-synuclein/GFP antibodies in a scanning confocal
microscope, the presence of a-synuclein in microglia was investigated
(E–F0). At the core of the human a-synuclein over-expression in the
AAV6|a-Syn animals, microglia were found with significantly changes
morphology and intra-cellular a-synuclein (E–E0). Interestingly, two
localization patterns were observed, both in the cell soma in circular,
vesicular structures and as small accumulations in distal processes of
the microglia. No such patterns were observed in AAV6|GFP (F–F0) or
intact controls.
doi:10.1371/journal.pone.0100869.g010
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hippocampus or other parts of the temporal lobe. The absence of
synucleinopathy in this region is consistent with the absence of
spatio-visual memory deficits in the MWM, a test known to be
highly hippocampus dependent [37].
In post-mortem analysis performed at 40 weeks post injection,
i.e. when the rats had reached 9 months of age, the animals
displayed a multifaceted degenerative pattern with a number of
very interesting pathological features. Isotropic fractionation based
quantification showed an overall loss of cortical neurons of more
than 20% in the AAV6|a-Syn animals. Such a loss is impressive in
the light of that the entire cerebral cortex was included in this
counting and, as the expression of a-synuclein is primarily in the
frontal parts, the degeneration in this region is most likely even
greater. In addition, widespread a-synuclein –induced pathology
was present in many surviving neurons, associated with wide-
spread microglial activation. a-Synuclein was distributed diffusely
throughout the neuronal cytoplasm and also as puncta and
inclusion bodies of varying size in both the soma and the nucleus.
Immunogold staining on EM sections revealed that a-synuclein
formed fibrillar-like structures as well as larger inclusion bodies
within the transduced neurons.
Phosphorylated a-synuclein was observed in the form of small
puncta within larger inclusion bodies present in the cytoplasm,
supporting the notion that phosphorylation is important for
aggregation, though not absolutely required [38]. However, this
still remains an open question and there are studies showing that
S129 phosphorylation has a negative effect on aggregation [39].
Therefore, the phosphorylation may also have happened after the
synuclein accumulated. It remains to be shown if the amounts of
phosphorylation in this model follows the amount of human a-
synuclein over-expression or if it is increased to an even larger
extent, then suggesting a potential seeding effect of the human a-
synuclein on the endogenous protein. Interestingly, phosphorylat-
ed a-synuclein was commonly associated with the cell nucleus
[40,41]. This is an important finding as nuclear localization may
further aggravate neuronal toxicity [42]. Indeed, electron micros-
copy analysis revealed that neurons with large amounts of human
a-synuclein present within the nucleus often presented with a
degenerative morphology.
Human a-synuclein was observed to be anterogradely trans-
ported along the cortico-thalamic and cortico-spinal tracts, as well
as in striatal projection neurons. This fits well with previous studies
showing that a-synuclein plays a role in synaptic function [43–45].
Although found in some neuronal projections, phosphorylated a-
synuclein was not as common there as non-phosphorylated a-
synuclein, especially in longer projections, suggesting that phos-
phorylation impacts anterograde axonal transport of a-synuclein in
vivo. This is in line with previous studies showing that phosphor-
ylation of a-synuclein attenuate axonal transport in cultured
neurons [46]. Human a-synuclein was a common finding in
numerous axonal swellings, localized not only in the cortex but
also within the striatum, thalamus and SNpr. The axonal swellings
indicate that a-synuclein over-expression causes blockages or
disruption of axonal trafficking, which would further contribute to
pathology and neuronal degeneration [46,47].
In this study we also chose to study one cellular subtype of
interest in the normal function of the forebrain, the cholinergic
interneurons. Cholinergic interneurons have recently received
increased attention, as they are important for intrinsic regulation
of a wide range of behaviors, including associative learning [48],
reward processing [49], depression [50] and dyskinesias in PD
[51]. Furthermore, a decrease in forebrain acetylcholine levels is
observed in many DLB cases and pathological changes in
cholinergic interneurons may be a contributor to this disease
phenotype [52].
Stereological counting showed a progressive loss of ChAT+
interneurons, both in striatum and cortex of AAV6|a-Syn
animals. While variable, we found up to a 50% reduction of
ChAT+ interneurons both in the striatum and in the cortex. This
is a proportionally greater reduction than we observed in the total
loss of neurons in the cortex using the isotropic fractionation,
indicating that cholinergic interneurons may be more vulnerable
to a-synuclein toxicity than other sub-types of cortical neurons.
Consistent with the widespread a-synuclein-induced pathology
the AAV6|a-Syn animals displayed significantly increased loco-
motor behavior in the open field task, linked to a decreased
locomotor response to apomorphine. While there are many
possible functional explanations for this particular phenotype, a-
synuclein mediated pathology and loss of cholinergic interneurons
in the striatum, provides one possible mechanism. Both cholinergic
and GABAergic interneurons in the striatum play a major role in
modulating output from the medium spiny neurons to the direct
and indirect pathways [53,54]. Cholinergic interneurons within
the striatum work in close proximity with dopaminergic synapses
and modulate dopamine release and the response of the medium
spiny neurons to dopamine agonists [55]. It is also worth to note
that while the degeneration of striatal cholinergic interneurons is
not a prominent feature in either DLB or other forms of dementia,
they have been shown to be affected in related disorders such as
supranuclear palsy (PSP) [56].
The utilization of both morphologic EM and immunogold
labeled EM in this study allowed us to study the a-synuclein-
induced toxic mechanisms in both soma and axons of degener-
ating and dysfunctional neurons. The pathological morphology
ranged from disruption of the nuclear membrane and distention of
the endoplasmatic reticulum, to apoptosis with evidence of
autophagy. Similar findings have recently been observed with
mutations of b-synuclein linked to DLB [57]. Autophagy
represents a major route for degradation of aggregated cellular
proteins and dysfunctional organelles and has emerged as an
interesting potential target for neuroprotective therapies, relevant
for both a-synuclein- and tau-induced toxicity [58–61]. Immuno-
gold staining also revealed that human a-synuclein had a strong
association to mitochondria. These mitochondria often presented
with a swollen pathological morphology, although this was not
always the case. Indeed, mitochondrial dysfunction has been
identified as one of the hallmarks of a-synuclein toxicity and is
thought to play a major role in neuronal degeneration [58,62].
Lastly, it is worth to stress that we through the neonatal
injection paradigm achieve widespread protein injection and
significant pathology without the requirement of exceptionally
high a-synuclein expression levels. In areas of most prominent
pathology, the total a-synuclein levels were increased to, on
average, two-fold. This is very similar to the levels observed in
patients with SNCA gene triplication (coding for a-synuclein) of
the Swedish-American kindred, which also displays severe
dementia, Parkinsonism and Lewy pathology both in cortex and
in the hippocampus [63]. However, individual neurons within the
transduced region may express relatively higher amounts.
Furthermore, as we in this model restrict expression of human
a-synuclein to the cerebrum, this opens up for peripheral studies of
wet biomarkers of disease progression, e.g., in CSF or blood, as any
human a-synuclein observed there can be directly attributed to
central expression.
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Concluding remarks
Viral vector gene delivery has shown great promise in
development of novel models replicating human monogenic
disease conditions in animals. Using this technique we have
created a novel animal model, based on over-expression of human
a-synuclein, that replicates the cortical neuronal degeneration and
pathology seen in DLB patients, without the confounding
contributions of midbrain and/or brainstem pathology. This
study has for the first time shown that cholinergic interneurons in
the cortex and striatum are selectively vulnerable to a-synuclein
induced toxicity and that early, AAV-mediated a-synuclein
delivery produces a progressive neurodegeneration with chronic
microglial activation. The pathology in this model replicates a
number of important findings in other in vivo models of a-synuclein
mediated toxicity, such as nuclear localization of phosphorylated
a-synuclein, swollen mitochondria with membrane associated a-
synuclein, increased autophagy, and microglial activation with a-
synuclein uptake. Therefore, this rat model could become very
useful for studies of novel disease modifying therapies.
Although we used human wild-type a-synuclein in our study,
the neonatal gene delivery approach described here may be used
investigate other, mutated forms of a-synuclein, and it will be
generally useful for studies involving widespread gene delivery to
neurons in the neocortex. We also propose that our animal model
may be used as a platform for discovering and evaluating novel
biomarkers, such as development of diagnostic imaging tools like
SPECT, PET and functional MRI. These may be used for
evaluating hypoperfusion, hypometabolism, and global grey
matter atrophy. Taken together, this model exhibiting a-synuclein
over-expression localized to the cortices provides significant
advantages over current transgenic models for evaluating the
mechanisms observed in conditions of widespread cortical a-
synuclein pathology, such as DLB.
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